+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 90Years
All Genders
ID05925023

Sirolimus Treatment for Adults with Refractory or Relapsed Warm Autoimmune Hemolytic Anemia or Evans Syndrome

Led by Peking Union Medical College Hospital · Updated on 2025-08-08

22

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Warm autoimmune hemolytic anemia wAIHA is a rare disorder where the bodys immune system destroys its own red blood cells using warm or cold antibodies. The usual first treatment combines glucocorticoids with rituximab, but many patients either relapse or do not respond well. Other treatments include cyclosporine A, cyclophosphamide, rituximab alone, azathioprine, or splenectomy. Previous studies showed promising results with sirolimus for patients whose disease is hard to treat or has returned, so this trial explores sirolimuss effectiveness and safety for refractory or relapsed wAIHA. In this prospective trial, patients with refractory or relapsed primary wAIHA will receive oral sirolimus at doses of 1 to 3 mg per day, aiming for a blood concentration between 4 and 15 ngmL. Treatment is planned for at least six months. Patients who respond well will continue sirolimus for one more year before gradually reducing the dose. This approach hopes to provide a more accessible and affordable option for patients compared to other second-line therapies. Participants will be monitored over time to evaluate how well they respond to sirolimus at 3, 6, and 12 months, including the overall response rate and complete response rate. Researchers will also check for any treatment-related side effects, relapses, and other adverse events during this period. The study aims to improve quality of life and reduce complications like infections or cardiovascular events in patients with refractory or relapsed wAIHA. Total study involvement may last beyond one year depending on treatment response and follow-up needs.

CONDITIONS

Brief Title

Sirolimus in the Treatment of Refractory/Relapsed wAIHA

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here